Sustained effect of SQ‐standardized grass allergy immunotherapy tablet on rhinoconjunctivitis quality of life
Authors:
Abstract
To cite this article: Frølund L, Durham SR, Calderon M, Emminger W, Andersen JS, Rask P, Dahl R. Sustained effect of SQ‐standardized grass allergy immunotherapy tablet on rhinoconjunctivitis quality of life. Allergy 2010; 65: 753–757. Background: The prevalence of allergic rhinoconjunctivitis has increased significantly over the past decades with grass pollen being a common trigger. The impact of allergy on patient’s quality of life is substantial.Aim: To investigate the sustained effect on quality of life during the grass pollen season 1 year after 3 years of treatment with the SQ‐standardized grass allergy immunotherapy tablet (AIT), Grazax® (Phleum pratense 75,000 SQ‐T/2800 BAU; ALK, Denmark).Methods: The trial was a randomized, parallel‐group, double‐blind, placebo‐controlled trial in adult subjects with a history of moderate‐severe grass pollen induced rhinoconjunctivitis inadequately controlled by symptomatic medications. Subjects received 3 years of grass AIT (n = 157) or placebo (n = 126), followed by 1 year of follow‐up. Quality of life assessments were based on the standardized rhinoconjunctivitis quality of life questionnaire (RQLQ(S)); completed weekly during the entire grass pollen season.Results: During follow‐up, the overall RQLQ(S) score for the entire grass pollen season was significantly improved in the active group (relative difference to placebo: 23%, P = 0.004). The improvement was higher during the peak pollen season (28%, P = 0.001). The treatment effect of grass AIT during the follow‐up year and the previous three treatment years was similar. Improvements were found in all seven RQLQ(S) domains. The RQLQ(S) as a function of the weekly average pollen counts showed a clear separation between the treatment groups (P < 0.001).Conclusion: In subjects inadequately controlled by symptomatic medications, grass AIT provided sustained and clinically relevant improvements in rhinoconjunctivitis quality of life compared to placebo. The effect increased with increasing grass pollen exposure.Keywords
This publication has 12 references indexed in Scilit:
- Long-term clinical efficacy in grass pollen–induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tabletJournal of Allergy and Clinical Immunology, 2010
- Original article: Quality of life in rhinoconjunctivitis assessed with generic and disease‐specific questionnairesAllergy, 2008
- The voice of the patients: allergic rhinitis is not a trivial diseaseCurrent Opinion in Allergy and Clinical Immunology, 2008
- A survey of the burden of allergic rhinitis in the USAAllergy, 2007
- Seasonal allergic rhinitis is associated with a detrimental effect on examination performance in United Kingdom teenagers: Case-control studyJournal of Allergy and Clinical Immunology, 2007
- Development and validation of an electronic version of the Rhinoconjunctivitis Quality of Life QuestionnaireAllergy, 2007
- Nasal Symptoms Are Associated with School Performance in AdolescentsJournal of Adolescent Health, 2007
- The burden of allergic rhinitisAllergy and Asthma Proceedings, 2007
- Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire☆☆☆★Journal of Allergy and Clinical Immunology, 1999
- Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitisClinical & Experimental Allergy, 1991